Zoetis (ZTS) Short term Debt (2012 - 2025)

Zoetis (ZTS) posted quarterly Short term Debt of $1.4 billion for Q2 2025, little changed quarter-over-quarter from $1.4 billion in Q1 2025.

Zoetis (ZTS) Short term Debt (2012 - 2025) Analysis & Trends

Zoetis (ZTS) has reported Short term Debt for 12 consecutive years, with $1.4 billion the latest figure, recorded in Q2 2025.

In Q2 2025, Short term Debt changed N/A year-over-year to $1.4 billion; the TTM figure through Jun 2025 stood at $1.4 billion (changed N/A YoY), while the FY2024 annual figure was $1.4 billion, changed N/A from the prior year.
Short term Debt held at $1.4 billion in Q2 2025 per ZTS's latest filing, from $1.4 billion in the prior quarter.
Across five years, Short term Debt topped out at $1.4 billion in Q1 2022 and bottomed at $2.0 million in Q2 2022.
Historically, Short term Debt has averaged $553.0 million across 5 years, with a median of $312.0 million in 2021.
Annual changes were most pronounced in 2023 — Short term Debt sank 99.78% — and 2025, when it surged 5525.0%.
Zoetis' Short term Debt stood at $600.0 million in 2021, then tumbled by 99.67% to $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then soared by 67400.0% to $1.4 billion in 2024, then changed by 0.0% to $1.4 billion in 2025.
Business Quant data shows ZTS's Short term Debt at $1.4 billion in Q2 2025, $1.4 billion in Q1 2025, and $1.4 billion in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Alkermes	8.02 Bn	7.37 Bn	397.90 Mn

Download Data